The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public CROs saw their stock prices rise as well. In 2014, the clinical development industry saw an increased shift toward Risk-Based Monitoring methodologies and an increased reliance on eClinical technologies. More: http://bit.ly/1w9gIOn

1. ISR’s Clinical Development
ISRreports.com | info@ISRreports.com | @ISRreports
The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public
CROs saw their stock prices rise as well. In 2014, the clinical development industry saw an increased shift
toward Risk-Based Monitoring methodologies and an increased reliance on eClinical technologies. For more
information on these trends and ISR’s CRO market size projections through 2018, visit www.ISRreports.com.
percent growth
Pharma & Biotech
Stock Index
+32.5%
CRO Stock Price
(Q, PRXL, CVD, ICON,
CRL) +16.2%
3Q 2013 3Q 2014
Pharma R&D
-4.5%
eClinical technology continued to play a
growing role in clinical development in
2014. ISR’s research found that
“integration” is gaining the most importance
among eClinical system users.
ISR’s respondents said they integrate
CTMS applications with:
IRT systems 17%
of the time
2014 saw even more CROs going public, a trend that
PAREXEL’s SVP and CFO, Ingo Bank, said he expects
to continue in the coming years.
Merger and Acquisition activity in the
Pharmaceutical and Life Science Industry
continued to grow in 2014.
Total deal value (Q1-Q3):
Number of Investigational New Drug applications, by quarter
Increasing use of multiple countries
Technology becoming increasingly critical
Growing use of RBM Expansion of preferred provider lists
China becoming more common for subject recruitment
More complex trials eClinical data integration on the rise
2014 saw an increase in the number of clinical trials using Risk-Based
Monitoring. For details on the growth and implementation of RBM, see
ISR’s “The Evolution of Risk-Based Monitoring” infographic.
65% of ISR
respondents
consider their
volume of risk-based
monitoring in Phase
II/III studies to be
increasing.
65% 40%
ISR respondents
report that 40%
of their Phase
II/III studies
include
risk-based
monitoring.
EDC IRT ePRO
EDC systems 44%
of the time
Already Public 2014 IPO
ePRO systems
15% of the time
ISR Research
fda.gov
google.com/finance
ISR’s ”CTMS Market Dynam-ics
and Service Provider
Benchmarking”
ISR’s “The Evolution of
Risk-Based Monitoring
PwC
Thomson Reuters
ICON
PAREXEL
Covance
Quintiles
PRA
INC
RESEARCH
Oct.-
Dec.
2012
Jan. -
March
2013
April -
June
2013
July -
Sept.
2013
Oct. -
Dec.
2013
Jan. -
March
2014
April -
June
2014
July -
Sept.
2014
66 78
176
92
107
Q3
Q2
Q1
$79B
$106B
$121B
$21B
$21B
2012
$18B
$11B
$77B
$61B
$15B
$45B
$37B
2013 2014
72 64
93